Lupin’s wholly-owned subsidiary, Nanomi BV, signed a definitive agreement to fully acquire Amsterdam-headquartered VISUfarma BV at an enterprise value of 190 million euros. VISUfarma is a portfolio company of global healthcare investor GHO Capital Partners LLP, and the acquisition marks a significant step in Lupin’s strategy to expand its European business and specialty franchise.
Strengthening Lupin’s Ophthalmology Portfolio
VISUfarma brings a broad portfolio of over 60 branded eye health products and an established commercial infrastructure across Europe. The acquisition will allow Lupin to tap into the high-growth ophthalmology market, driven by factors such as:
*An aging global population
*Rising diabetes-related eye complications
*Increased awareness of preventive eye care
By integrating VISUfarma’s operations, Lupin aims to accelerate growth in Europe and enhance its specialty segment presence globally.
Expanding European Footprint
VISUfarma’s established operations across key European countries, including Italy, the UK, Spain, Germany, and France, will provide Lupin with:
*A direct market presence
*Opportunities for geographic expansion
*Business diversification within the European ophthalmology sector
The integration is expected to support Lupin’s long-term growth strategy and solidify its position in the specialty care segment.
Targeted nutraceuticals
Vinita Gupta, CEO of Lupin, stated, “This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve. Beyond being immediately accretive, it broadens our presence in Europe and further builds our specialty franchise in ophthalmology.”
Strategic and Financial Outlook
Lupin will finance the acquisition using its existing cash reserves. Analysts expect it to boost the company’s growth and margin profile. The company projects completing the transaction by the end of 2025, subject to standard closing conditions.
Paolo Cioccetti, CEO Italy, VISUfarma, added, “As part of Lupin’s ophthalmology operations, we will build towards a global ophthalmology franchise with a commitment to advancing eye care and improving patient outcomes.”
Driving Specialty Growth Globally
As reported by thehindubusinessline.com, with VISUfarma’s portfolio and operations, Lupin is positioned to strengthen its specialty franchise, enhance product offerings in ophthalmology, and expand its footprint across Europe. The acquisition underscores the company’s strategic focus on high-growth therapeutic areas and its commitment to improving patient outcomes worldwide.
